OPKO Health, Inc. (NYSE: OPK) has been awarded a contract and selected
to participate in a development project directed by NASA to implement
the OPKO point-of-care diagnostic platform (Claros-1™) with the
objective of in-orbit use on the International Space Station.
OPKO will provide a panel of assays, including Vitamin D for bone
metabolism, immune health, and inflammation to be used on its Claros-1™
portable analyzer. According to Phillip Frost, M.D., OPKO's Chairman and
Chief Executive Officer, "This contract is an opportunity to demonstrate
the robustness and ease-of-deployment of the OPKO point-of-care system
as well as the wide range of complex and high performance diagnostic
tests which can be rapidly implemented for use in any environment."
About OPKO Health, Inc.
We are a multi-national biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large and rapidly
growing medical markets by leveraging our discovery, development and
commercialization expertise and our novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding our ability to successfully
develop the Claros-1™ system for in-orbit use on the International Space
Station, our ability to successfully commercialize the Claros-1™ system,
our ability to demonstrate the robustness and ease-of-deployment of the
Claros-1™ system for use in any environment and other non-historical
statements about our expectations, beliefs or intentions regarding our
business, technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or results to
differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in our
filings with the Securities and Exchange Commission, as well as risks
inherent in funding, developing and obtaining regulatory approvals of
new, commercially-viable and competitive products and treatments. In
addition, forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin, 305-575-4100
Source: OPKO Health, Inc.
News Provided by Acquire Media